Unique forum will unite NHS and industry to drive innovation
April 18, 2018 |
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines,
by Sarah Eglington, Client Services Director at Wilmington Healthcare
The Life Sciences Industrial Strategy made it clear that collaboration between the NHS and industry is essential to foster innovation. To help facilitate this process, HSJ which is part of Wilmington Healthcare, will host a unique Life Sciences Forum on Wednesday, June 6.
Senior representatives from pharma, med tech and the NHS are invited to attend this exclusive event at BMA House in London, which will feature presentations from high profile speakers within the healthcare sector and opportunities for guests to join in the discussions.
The event aims to help industry develop stronger relationships with leaders from NHS England, Regional Medicines Optimisation Committees (RMOCs), Sustainability and Transformation Partnerships (STPs) and Integrated Care Systems (ICSs), and influence debate around the future direction of travel for medicines.
It will also help industry to better understand the challenges facing the NHS by learning about its priorities at a local and national level. Guests can find out about partnership working approaches through collaboration with Academic Health Science Networks (AHSNs) too.
The Life Sciences Forum is designed to enable both parties to have honest and candid discussions on how to develop relationships and drive innovation to ensure patient outcomes are improved and efficiencies are realised. More than 50 people have contributed to background research to ensure the event programme meets the needs of both the pharma and med-tech sectors, as well as the NHS.
Key speakers
Speakers will include the ministerial lead for life sciences policy and NHS innovation, Lord O’Shaughnessy, who will lead the first keynote session on the theme of ‘Implementing the Life Sciences Industrial Strategy’.
The second keynote session of the day on the theme of ‘Strengthening collaboration with NHS and industry’, will be led by Ian Dodge, National Director, Strategy and Innovation, NHS England.
Another key speaker will be Steve Oldfield, the Department of Health and Social Care’s chief commercial officer and the person charged with renegotiating the £8bn pharmaceutical pricing regulation scheme, who will be a panellist on a session about ‘Negotiating the PPRS – Assessing what comes next’.
Representatives from NICE, MHRA and ABPI will also be among those involved in the wide-ranging debates which will help guests to understand how to develop relationships with and deliver innovation to the NHS.
An overview of the agenda ·
Candid and open discussion about access and pricing as the deadline for completing PPRS negotiations rapidly approaches ·
Keynote sessions in which NHS England and STP leaders outline their strategic vision and what role the life sciences sector can play in supporting it ·
Lively debate about the Life Sciences Industrial Strategy and how barriers between industry and NHS can be broken down to realise its goals ·
Opportunity for industry and the newly established RMOCs to engage in a dialogue about medicines optimisation and what specific challenges the NHS faces in terms of eliminating waste and variation to meet the efficiency agenda ·
Breakout sessions in which AHSNs, industry and the NHS can discuss service redesign, patient pathways and the innovation from industry that’s required to deliver an ambitious programme of transformation ·
Clarity on the role of NICE and the chance to feedback on the Health Technology Assessment (HTA) process ·
Increased knowledge of the challenges and changes in the NHS at a national level in terms of specialised commissioning and at a local level
Conclusion
There is a pressing need for the pharma and med tech sectors to work more closely with the NHS, to maximise value for money while also ensuring access to innovative medicines and devices. The HSJ Life Sciences Forum is a unique opportunity for industry and the NHS to come together to discuss their challenges and identify solutions.
For more information about the event and details on how to sign up for it, please visit https://lifesciences.hsj.co.uk/
Ends
Sarah Eglington is Client Services Director at Wilmington Healthcare. For information on Wilmington Healthcare, log on to www.wilmingtonhealthcare.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...